logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Artbio Raises Oversubscribed And Upsized $90 Million Series A Financing To Progress Pipeline And Isotope Technology Development For New Class Of Alpha Radioligand Therapies

Dec 07, 2023•about 2 years ago

Amount Raised

$90 Million

Round Type

series a

CambridgeBiotechnology

Investors

Omega FundsF Prime CapitalThird Rock Ventures

Description

ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), today announced the closing of an oversubscribed and upsized $90 million Series A financing co-led by Third Rock Ventures and an undisclosed healthcare fund. Additionally, seed lead investors F-Prime Capital and Omega Funds participated substantially. The company's prior seed investment round of $23 million was announced in June 2023.

Company Information

Company

Artbio

Location

Cambridge, Massachusetts, United States

About

Artbio is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

Related People

3 contacts

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech